Shares of Medpace Holdings Inc (NASDAQ:MEDP) have been given an average recommendation of “Buy” by the five brokerages that are covering the firm. Two analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $35.00.

Several research analysts recently commented on MEDP shares. Jefferies Group reiterated a “hold” rating on shares of Medpace Holdings in a research report on Tuesday, October 4th. Credit Suisse Group AG started coverage on Medpace Holdings in a research report on Tuesday, September 6th. They issued an “outperform” rating and a $35.00 price target for the company. Robert W. Baird started coverage on Medpace Holdings in a research report on Tuesday, September 6th. They issued a “neutral” rating and a $35.00 price target for the company. William Blair restated an “outperform” rating on shares of Medpace Holdings in a research report on Tuesday, September 6th. Finally, Wells Fargo & Co. started coverage on Medpace Holdings in a research report on Tuesday, September 6th. They set an “outperform” rating for the company.

Shares of Medpace Holdings (NASDAQ:MEDP) opened at 29.69 on Tuesday. The stock’s market cap is $969.14 million. Medpace Holdings has a 1-year low of $26.51 and a 1-year high of $31.35. The company has a 50 day moving average price of $29.57 and a 200 day moving average price of $29.38.

In related news, CEO August J. Troendle acquired 869,565 shares of the company’s stock in a transaction dated Tuesday, August 16th. The shares were purchased at an average cost of $23.00 per share, with a total value of $19,999,995.00. Following the completion of the acquisition, the chief executive officer now directly owns 1,221,416 shares of the company’s stock, valued at $28,092,568. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Susan E. Burwig acquired 19,211 shares of the company’s stock in a transaction dated Wednesday, August 17th. The shares were bought at an average cost of $29.21 per share, for a total transaction of $561,153.31. Following the completion of the acquisition, the insider now directly owns 1,211 shares of the company’s stock, valued at $35,373.31. The disclosure for this purchase can be found here.

A hedge fund recently bought a new stake in Medpace Holdings stock. Creative Planning acquired a new position in shares of Medpace Holdings Inc (NASDAQ:MEDP) during the third quarter, according to its most recent filing with the SEC. The fund acquired 4,348 shares of the company’s stock, valued at approximately $130,000.

About Medpace Holdings

Medpace Holdings, Inc is a holding company. The Company operates as a clinical contract research organization (CRO) focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company is focused on conducting clinical trials across therapeutic areas, with focus in cardiology, metabolic disease, oncology, endocrinology, central nervous system (CNS), and Anti-Viral and Anti-Infective (AVAI).

5 Day Chart for NASDAQ:MEDP

Receive News & Stock Ratings for Medpace Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace Holdings Inc and related stocks with our FREE daily email newsletter.